Mon.Oct 21, 2024

article thumbnail

Novo plots US, EU approval filings after oral semaglutide shows cardio benefits in certain diabetes patients

Fierce Pharma

As Novo Nordisk’s injectable diabetes-obesity duo Ozempic and Wegovy grab all the limelight, an oral version of the semaglutide drug showed it can provide heart-related benefits, too. | As Novo Nordisk’s injectable diabetes-obesity duo Ozempic and Wegovy grab all the limelight, an oral version of the semaglutide drug showed it can provide heart-related benefits, too.

Patients 320
article thumbnail

Can Primary Care Thrive Outside of Traditional Healthcare Players?

MedCity News

Recent failures in the retail health space beg the question: Is primary care only suited to remain within traditional players? Four healthcare executives shared their responses to this question during a panel at HLTH in Las Vegas. The post Can Primary Care Thrive Outside of Traditional Healthcare Players? appeared first on MedCity News.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Sanofi in 'exclusive negotiations' to sell 50% stake in €16B consumer health unit Opella

Fierce Pharma

Sanofi is now in “exclusive negotiations” with U.S. | Sanofi is now in “exclusive negotiations" with U.S. private equity firm Clayton, Dubilier & Rice to sell a 50% controlling stake in its consumer health business Opella, the company said. The deal values the consumer group at 16 billion euros.

274
274
article thumbnail

Blue Shield of California, Salesforce Partner to Modernize Prior Authorization

MedCity News

During HLTH 2024, Blue Shield of California and Salesforce announced a partnership that will streamline the prior authorization process. The post Blue Shield of California, Salesforce Partner to Modernize Prior Authorization appeared first on MedCity News.

114
114
article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

Activist investor Starboard sets its sights on J&J spinout Kenvue: WSJ

Fierce Pharma

Activist investor Starboard Value, which picked up a $1 billion stake in Pfizer earlier this month, now reportedly has Johnson & Johnson’s consumer health spinout Kenvue in its sights. | Starboard, which recently pitched turnaround plans to Pfizer, reportedly thinks the J&J consumer health spinout's stocks have underperformed since its market debut over a year ago.

Marketing 253
article thumbnail

Astellas Pharma Lands a First-in-Class Drug Approval in Rare Gastrointestinal Cancer

MedCity News

The FDA approved Astellas’s Vyloy as a treatment for advanced cases of gastric or gastroesophageal junction (GEJ) adenocarcinoma positive for a protein called claudin 18.2. It’s the first FDA-approved therapy for this target. The post Astellas Pharma Lands a First-in-Class Drug Approval in Rare Gastrointestinal Cancer appeared first on MedCity News.

Pharma 108

More Trending

article thumbnail

How the Move of Ablation Procedures into Surgery Centers Will Transform Electrophysiology

MedCity News

Within a matter of months, we’re likely to see substantial growth in the number of EP ablation procedures performed in surgery centers outside the hospital. Here’s what we can expect. The post How the Move of Ablation Procedures into Surgery Centers Will Transform Electrophysiology appeared first on MedCity News.

109
109
article thumbnail

Takeda details another round of layoffs in Massachusetts as restructuring drive rolls on

Fierce Pharma

Following a series of layoff rounds this year, Takeda is once again pruning its headcount in the Bay State. | As part of a new round of layoffs, certain Takeda staffers at two Massachusetts sites are set to lose their jobs. This marks the third round of job cuts Takeda has initiated in the state since it revealed a large restructuring drive in May.

285
285
article thumbnail

Gilead, MSD say HIV combo could be weekly, oral HIV drug

pharmaphorum

An antiretroviral combination developed by Gilead and MSD suppressed HIV with a single weekly oral dose in a phase 2 trial reported at IDWeek 2024

118
118
article thumbnail

The Funding Model for Cancer Innovation is Broken — We Can Fix It

MedCity News

Closing cancer health equity gaps requires medical breakthroughs made possible by new funding approaches. The post The Funding Model for Cancer Innovation is Broken — We Can Fix It appeared first on MedCity News.

Medical 95
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Sales Territory Design: Simple 10-Step Process for Field Sales Teams

Spotio

Designing sales territories has never been more important for door to door and field sales teams. Unfortunately, designing sales territories is a process that the majority of sales managers rush through. Aligning territory design with business priorities is crucial, as poor planning is a major issue impacting sales reps’ ability to meet quotas.

article thumbnail

Seaport docks $225m for its improved neuropsychiatry drugs

pharmaphorum

Seaport Therapeutics completes a $225m Series B to fund its improved therapies for depression and anxiety, just months after raising $100m on its debut

102
102
article thumbnail

Embedding into the provider’s workflow is key to a specialty drug’s success

PharmaVoice

Providers struggle with time-consuming processes. Patients are waiting for therapy. Embedded EMR system solutions can streamline therapy initiation and improve outcomes.

article thumbnail

Roche trial confirms Vabysmo efficacy in minorities

pharmaphorum

A study has shown that Roche's diabetic macular oedema (DME) therapy Vabysmo is effective in patients who identify as African American, Black, Hispanic and Latino, plugging a gap in the data for the drug.Vabysmo (faricimab) has been approved by the FDA for treating DME since 2022, quickly becoming one of the Swiss pharma group's fastest-growing products with sales of $1.1 billion in the first half of the year.

FDA 92
article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

AAO 2024: Nanoscope Therapeutics’ MCO-010 RESTOREs vision in RP patients

Pharmaceutical Technology

This trial investigated the potential of Nanoscope Therapeutics' MCO-010 to restore vision in patients with retinitis pigmentosa (RP).

article thumbnail

PursueCare brings Pear addiction DTx apps back to life

pharmaphorum

Two digital therapeutics for addiction are available again through PursueCare, which acquired them from now-defunct Pear Tx last year

107
107
article thumbnail

AstraZeneca’s Polyneuropathy Treatment Recommended for EU Approval

PharmaTech

Wainzua had been previously approved for use by patients with ATTRv-PN in the United States, under the brand name Wainua.

Patients 105
article thumbnail

Novo Nordisk closes on EU okay for haemophilia antibody

pharmaphorum

Novo Nordisk's TFPI drug concizumab has been backed for approval in the EU to prevent bleeding episodes in people with haemophilia and inhibitors

92
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

FDA’s GLP-1 decision kicks off ‘unprecedented’ tussle over shortage

PharmaVoice

After initially declaring the shortage of Eli Lilly’s diabetes and weight loss drugs over, the FDA changed its mind and re-opened the door for GLP-1 compounders.

FDA 69
article thumbnail

Expecting the Unexpected

Pharmaceutical Commerce

In this video interview with Pharma Commerce Editor Nicholas Saraceno, Jeffrey Bernstein, director of cybersecurity and data privacy for Kaufman Rossin’s risk advisory services, explains the top mistakes healthcare organizations make when building and maintaining their software.

Pharma 64
article thumbnail

NICE recommends Santen’s Roclanda to treat glaucoma and ocular hypertension

PharmaTimes

Primary open-angle glaucoma affects around 2% of adults aged 40 years and older in the UK

90
article thumbnail

FDA approves Astellas’ VYLOY for gastric cancer treatment

Pharmaceutical Technology

Astellas Pharma has received approval from the FDA for VYLOY in conjunction with chemotherapy, for the treatment of advanced gastric cancer.

FDA 69
article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

Learna and University of Wolverhampton launch flexible healthcare courses

PharmaTimes

The five new programmes are designed to fit alongside full-time work and clinical practice

article thumbnail

AAPS PharmSci 360: LBFs and Tackling Oral Biologic Formulations

PharmaTech

At AAPS PharmSci 360, Karunakar Sukuru, RPh, PhD, the global vice-president-Rx Product Development, Pharma and Consumer Health, at Catalent Pharma Solutions, discussed lipid-based formulations and tackling bioavailability challenges for oral biologics.

Pharma 52
article thumbnail

Drug combination shows promise for mitigating microbial biofilms

European Pharmaceutical Review

For the first time, a study has described the success application of a combination of allicin and domiphen to “control biofilm formation by pathogenic microorganisms”. Specifically, the two small molecule drugs were studied against the pathogens Staphylococcus aureus , Escherichia coli , and Candida albicans. The combination reduced the dosage of the two drugs and “demonstrated improved antimicrobial and anti-biofilm properties”.

article thumbnail

AAPS PharmSci 360: Challenges and Trends in Softgel Formulations

PharmaTech

Karunakar Sukuru, RPh, PhD, the global vice-president-Rx Product Development, Pharma and Consumer Health, at Catalent Pharma Solutions, spoke on recent challenges and trends in softgel formulations.

Pharma 52
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

[Sponsored Content] Patient Engagement Throughout the Entire Product Lifecycle

PharmExec

In the pharmaceutical industry, patient engagement should be centered in health education, communication, and strategy during drug discovery and throughout the product lifecycle. Cheryl Lubbert, CEO of Reverba, discusses the importance of a patient-first mindset in the industry.

article thumbnail

Enabling site success: Key insights to reducing burden and increasing access

pharmaphorum

In a new webinar with Atlas Clinical Research’s Chief Executive Officer Mark Scullion and Terttu Haring, President of Sites & Patients at Syneos Health and former investigator, learn more about the site experience for clinical research sites – including the important need for a partner who understands the challenges and drives solutions that can ease burden, create a better experience, and expand access and representation in clinical research for patients.

article thumbnail

AAPS PharmSci 306: Trends in New Analytical Tools for RNA Characterization

PharmaTech

Bala Addepalli, PhD, Director, R&D New Modalities Portfolio, Waters Corporation, discussed trends in new analytical tools for RNA characterization and gave highlights of his talk at AAPS PharmSci 360.

52
article thumbnail

Will Pharma Increase Use of Personalized Audio Use in Marketing?

PharmExec

In this part of her video interview, Amanda Powers-Han, Chief Marketing Officer, Greater Than One and Pharmaceutical Executive Advisory Board Member discusses how personalized audio will be utilized within the pharma marketing industry in 2025.

article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A